Hemagglutinin HA (A/Wisconsin/67/2022)(H1N1)-pdm09-Like
|
Catalog Number:
IA-H1-W22tp
|
|
Glycosylated recombinant influenza full-length hemagglutinin (A/Wisconsin/67/2022)(H1N1)-pdm09-like
|
Price: Starting at $219.00
Detailed Description
|
IA-H1-W22tp
|
|
Name
|
Hemagglutinin HA (A/Wisconsin/67/2022)(H1N1)-pdm09-like
|
|
Description
|
C-terminal 8x His-tagged glycosylated influenza full-length hemagglutinin HA (amino acid 18-530)(H1N1) (A/Wisconsin/67/2022)-pdm09-like (GISAID accession#: EPI_ISL_15928563), recommended FLU vaccine virus strain by WHO and FDA for the 2023-2024, 2024-2025, and 2025-2026 seasons in North America. A trimerization domain sequence has been introduced into the C-terminal of HA to stabilize the formation of trimer HA
|
|
Source
|
Glycosylated recombinant hemagglutinin protein expressed and purified from HEK293 cells
|
|
Application
|
Western Blot standard, antibody ELISA, antigen, etc.
|
|
Purity
|
> 95% (SDS-PAGE)
|
|
Endotoxin
|
<0.01 EU per µg of purified protein by LAL test
|
|
Size
|
50 µg
|
|
For Downloading
|
==>> Data Sheet ==>> Safety Data Sheet
|
About Influenza A Virus Hemagglutinin (HA) Recombinant Protein (A/Wisconsin/67/2022, H1N1pdm09)
Influenza A virus is an enveloped, negative-sense segmented RNA virus belonging to the family Orthomyxoviridae. Hemagglutinin (HA) is the major viral surface glycoprotein responsible for viral attachment to sialic acid-containing receptors on host cells and initiation of membrane fusion during viral entry. As the principal surface antigen, HA is the primary target of neutralizing antibodies and seasonal influenza vaccines. The A/Wisconsin/67/2022 (H1N1)pdm09 strain was selected by the World Health Organization (WHO) as the cell culture-, recombinant protein-, and nucleic acid-based H1N1 vaccine component for the 2023–2024 and 2024–2025 Northern Hemisphere influenza seasons, making it an important reference strain for influenza surveillance, vaccine development, and immunological research.
eEnzyme's Influenza A/H1N1pdm09 Hemagglutinin (HA) Recombinant Protein (A/Wisconsin/67/2022) is produced for research use and is suitable for antibody screening, receptor-binding studies, ELISA development, Western blotting, epitope mapping, structural characterization, and influenza vaccine research. This recombinant protein provides a valuable reagent for investigating influenza virus biology, host immune responses, and antiviral therapeutic development.
Applications
• Influenza H1N1 HA research
• Neutralizing antibody screening
• Receptor-binding studies
• ELISA and Western blot assays
• Epitope mapping
• Structural biology studies
• Influenza vaccine research
• Antiviral therapeutic development
Biological Significance of Influenza Hemagglutinin
Influenza HA is the functional viral attachment and fusion protein that initiates infection by recognizing sialic acid receptors on susceptible host cells. As the dominant antigen recognized by protective antibodies, HA remains the primary target for seasonal influenza vaccines and therapeutic antibody development. The Influenza A/H1N1pdm09 Hemagglutinin (HA) Recombinant Protein (A/Wisconsin/67/2022) provides a valuable research tool for studies of influenza virus pathogenesis, immune responses, vaccine evaluation, and diagnostic assay development.
|
|
|